Literature also suggests the two genes’ potential roles in breast cancer: a methylation study found NXPH1 as a candidate biomarker gene for HER2+ breast cancer (Lindqvist et al., 2014); an RNA-seq study found TSC22D4 up-regulated in a BRCA1 mutated cell line (SL) compared to a BRCA1 wild-type cell line (SB) (Privat et al., 2018); another study identified TSC22D2, an isoform of TSC22D4, as a novel cancer-associated gene in a rare multi-cancer family (Liang et al., 2016). This evidence concerns the gene NXPH1 and cancer.